The position of 99mTc-HYNIC and the molecular design of the DARPin G3 constructs influence the selection of an imaging tracer to detect expression in HER2-expressing tumors; Journal of Radioanalytical and Nuclear Chemistry; Vol. 335
| Parent link: | Journal of Radioanalytical and Nuclear Chemistry.— .— New York: Springer Science+Business Media LLC. Vol. 335.— 2026.— P. 1945–1959 |
|---|---|
| Outros Autores: | , , , , , , , , , , , , , , |
| Resumo: | Title screen Purpose The objective of the present study was to test the hypothesis that the position of the HYNIC chelator in DARPin G3 variants affects in vivo biodistribution and to select the most effective variant as a 99mTc imaging agent for HER2-expressing tumors. Methods This study evaluated the labelling, affinity, cellular processing, biodistribution, and in vivo targeting specificity of novel N- and C-terminal DARPin G3-HYNIC constructs. In addition, amino acid sequences containing E3C or (G3S)3C at the N- and C-terminus of the protein were used as linkers for HYNIC binding to DARPin G3 to enrich the molecular design of constructs in this study. Results The results demonstrated that the position of the HYNIC chelating group in DARPin G3 constructs did not affect the binding properties of the target in vitro and in vivo. At the same time, the position of HYNIC was found to strongly influence the biodistribution of labelled DARPin G3 constructs in CD1 mice, showing increased accumulation in the kidneys and decreased levels in the liver, spleen, and lungs when HYNIC was added to the N-terminus of the protein variants. Conclusion New N- and C-terminal constructs of DARPin G3-HYNIC were generated for HER2 targeting. It is evident that changing the position of the chelator in DARPin G3-HYNIC leads to differences in pharmacokinetic behaviour. The biodistribution of HYNIC variants attached to the N- or C-terminus of DARPin G3 was not significantly altered by different amino acid linkers. Therefore, variants with HYNIC positioned at the N-terminus are more useful for selecting a 99mTc-DARPin G3 imaging tracer. The [99mTc]Tc-HYNIC-C(G3S)3-G3 variant exhibited enhanced biodistribution compared to [99mTc]Tc-HYNIC-CE3-G3, particularly regarding reduced uptake in the liver AM_Agreement |
| Idioma: | inglês |
| Publicado em: |
2026
|
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1007/s10967-026-10739-w |
| Formato: | Recurso Eletrônico Capítulo de Livro |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=686120 |
MARC
| LEADER | 00000naa0a2200000 4500 | ||
|---|---|---|---|
| 001 | 686120 | ||
| 005 | 20260414160225.0 | ||
| 090 | |a 686120 | ||
| 100 | |a 20260414d2026 k||y0rusy50 ba | ||
| 101 | 0 | |a eng | |
| 102 | |a US | ||
| 135 | |a drcn ---uucaa | ||
| 181 | 0 | |a i |b e | |
| 182 | 0 | |a b | |
| 183 | 0 | |a cr |2 RDAcarrier | |
| 200 | 1 | |a The position of 99mTc-HYNIC and the molecular design of the DARPin G3 constructs influence the selection of an imaging tracer to detect expression in HER2-expressing tumors |f Maria Larkina, Ruslan Varvashenya, Anastasia Prach [et al.] | |
| 203 | |a Текст |b визуальный |c электронный | ||
| 283 | |a online_resource |2 RDAcarrier | ||
| 300 | |a Title screen | ||
| 320 | |a References: 63 tit | ||
| 330 | |a Purpose The objective of the present study was to test the hypothesis that the position of the HYNIC chelator in DARPin G3 variants affects in vivo biodistribution and to select the most effective variant as a 99mTc imaging agent for HER2-expressing tumors. Methods This study evaluated the labelling, affinity, cellular processing, biodistribution, and in vivo targeting specificity of novel N- and C-terminal DARPin G3-HYNIC constructs. In addition, amino acid sequences containing E3C or (G3S)3C at the N- and C-terminus of the protein were used as linkers for HYNIC binding to DARPin G3 to enrich the molecular design of constructs in this study. Results The results demonstrated that the position of the HYNIC chelating group in DARPin G3 constructs did not affect the binding properties of the target in vitro and in vivo. At the same time, the position of HYNIC was found to strongly influence the biodistribution of labelled DARPin G3 constructs in CD1 mice, showing increased accumulation in the kidneys and decreased levels in the liver, spleen, and lungs when HYNIC was added to the N-terminus of the protein variants. Conclusion New N- and C-terminal constructs of DARPin G3-HYNIC were generated for HER2 targeting. It is evident that changing the position of the chelator in DARPin G3-HYNIC leads to differences in pharmacokinetic behaviour. The biodistribution of HYNIC variants attached to the N- or C-terminus of DARPin G3 was not significantly altered by different amino acid linkers. Therefore, variants with HYNIC positioned at the N-terminus are more useful for selecting a 99mTc-DARPin G3 imaging tracer. The [99mTc]Tc-HYNIC-C(G3S)3-G3 variant exhibited enhanced biodistribution compared to [99mTc]Tc-HYNIC-CE3-G3, particularly regarding reduced uptake in the liver | ||
| 371 | 0 | |a AM_Agreement | |
| 461 | 1 | |t Journal of Radioanalytical and Nuclear Chemistry |c New York |n Springer Science+Business Media LLC. | |
| 463 | |t Vol. 335 |v P. 1945–1959 |d 2026 | ||
| 610 | 1 | |a труды учёных ТПУ | |
| 610 | 1 | |a электронный ресурс | |
| 610 | 1 | |a Designed ankyrin repeat proteins | |
| 610 | 1 | |a HER2 | |
| 610 | 1 | |a Imaging | |
| 610 | 1 | |a HYNIC | |
| 610 | 1 | |a 99mTc | |
| 701 | 1 | |a Larkina |b M. S. |g Mariya Sergeevna |f 1984- |c pharmacist |c Professor; Senior Researcher of the Tomsk Polytechnic University, Doctor of Pharmaceutical Sciences |9 22417 | |
| 701 | 1 | |a Varvashenya |b R. N. |c pharmacist |c engineer at Tomsk Polytechnic University |f 1997- |g Ruslan Nikolaevich |9 88559 | |
| 701 | 1 | |a Prach |b A. A. |g Anastasiya Aleksandrovna |f 1999- |c chemist |c engineer of Tomsk Polytechnic University |9 88930 | |
| 701 | 1 | |a Plotnikov |b E. V. |c chemist |c Associate Professor of Tomsk Polytechnic University, Candidate of Chemical Sciences |f 1983- |g Evgeny Vladimirovich |9 16417 | |
| 701 | 1 | |a Tretyakova (Tretjyakova) |b M. S. |c Medical technology specialist |c Research Engineer of Tomsk Polytechnic University |f 1994- |g Maria Sergeevna |9 22127 | |
| 701 | 1 | |a Eskova |b D. D. |g Darjya Dmitrievna |f 2003- |c biotechnologist |c laboratory assistant of Tomsk Polytechnic University |9 88808 | |
| 701 | 1 | |a Bodenko |b V. V. |c pharmacist |c engineer at Tomsk Polytechnic University |f 1997- |g Vitalina Vasiljevna |9 88553 | |
| 701 | 1 | |a Yanovich |b G. |c Pharmacist |c engineer of Tomsk Polytechnic University |f 1999- |g Gleb |9 89205 | |
| 701 | 1 | |a Shulga (Schulga) |b A. A. |c biologist |c Researcher, Tomsk Polytechnic University, Candidate of Biological Sciences |f 1960- |g Aleksey Anatolievich |9 22432 | |
| 701 | 1 | |a Konovalova |b E. V. |c specialist in the field of chemical technology and biotechnology |c engineer at Tomsk Polytechnic University |f 1985- |g Elena Valerjevna |9 88562 | |
| 701 | 1 | |a Ziganshin |b R. |g Rustam | |
| 701 | 1 | |a Belousov |b M. V. |c chemist |c Professor of Tomsk Polytechnic University, Doctor of Pharmaceutical Sciences |f 1963- |g Mikhail Valerievich |9 21924 | |
| 701 | 1 | |a Chernov |b V. I. |c specialist in the field of medical technology |c lead engineer of Tomsk Polytechnic University, doctor of medical sciences |f 1962- |g Vladimir Ivanovich |9 17725 | |
| 701 | 1 | |a Tolmachev |b V. M. |c specialist in the field of medical technology |c Director of the Research Center "Oncoteranostika", Tomsk Polytechnic University, Ph.D |f 1961- |g Vladimir Maksimilianovich |9 22210 | |
| 701 | 1 | |a Deev |b S. M. |c biologist |c Leading Researcher, Tomsk Polytechnic University, Doctor of Biological Sciences |f 1951- |g Sergey Mikhaylovich |9 20959 | |
| 801 | 0 | |a RU |b 63413507 |c 20260414 |g RCR | |
| 850 | |a 63413507 | ||
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10967-026-10739-w |z https://doi.org/10.1007/s10967-026-10739-w |
| 942 | |c CF | ||